Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

Illumina's (ILMN) preliminary fourth-quarter results, latest partnership deals and a robust pipeline of technologies instill investor optimism.

Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View

JD.com

These 2 Nasdaq Winners Are Lighting Up the Market Tuesday

Fourth-quarter 2021 results hit a "record," and Illumina's gearing up to report a big beat in 2022.

Why Illumina Stock Just Jumped 9.5%

At the J.P. Morgan Healthcare Conference, Illumina Inc (NASDAQ: ILMN) said it expects about $4.517 billion, +39% Y/Y in 2021 revenue after the company logged the highest number of international product shipments in its history, said CEO Francis deSouza during a presentation.

Why Are Illumina Shares Trading Higher Today?

Illumina, Inc. (ILMN) JPMorgan 40th Annual Healthcare Conference (Transcript)

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced a multi-year agreement to accelerate medicines development through large-scale genomics and the establishment of a preeminent clinico-genomic resource. Using Illumina's next-generation sequencing (NGS) platforms, scientists and researchers will be able to better identify disease associations and targets for intervention by analyzing data derived from VUMC's extensive, high-quality biobank of approximately 250,000 de-identified human DNA samples and associated longitudinal, structured medical data.

Illumina collaborates with Nashville Biosciences to accelerate medicines development

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a multi-year partnership with Agendia N.V., a world leader in precision oncology for breast cancer, to co-develop in vitro diagnostic (IVD) tests for oncology testing.

Illumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced a multi-year partnership with Illumina, Inc. (NASDAQ: ILMN), to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina's approach to IVD partnerships in oncology. Agendia joins Illumina's growin

Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed today the company's strong growth trajectory, including 2021 results and 2022 guidance. deSouza also announced new partnerships and technologies that will advance the company's mission of improving human health by unlocking the power of the genome.

Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC announced a collaboration with the Knight Cancer Institute at OHSU to offer the Galleri® multi-cancer early detection blood test.

Knight Cancer Institute at Oregon Health & Science University to Offer the Galleri® Multi-Cancer Early Detection Test

Premier

MENLO PARK, Calif. & CHARLOTTE, N.C.--(BUSINESS WIRE)--GRAIL, LLC, announced a collaboration with Premier, Inc.'s PINC AI™ to support patient access to the Galleri® multi-cancer early detection blood test.

GRAIL and Premier's PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test

SomaLogic

Illumina's (ILMN) collaboration with SomaLogic will boost the fast-growing high throughput sector of the proteomics market to aid research in biology and disease.

Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics

SAN DIEGO, Jan. 5, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan® Proteomics Assay onto Illumina's current and future high throughput next-generation sequencing (NGS) platforms. This partnership accelerates the rapidly growing high throughput sector of the proteomics market.

Illumina Enters Co-Development Partnership with SomaLogic

Illumina's (ILMN) recent collaboration will explore the real-world uptake and actionability of comprehensive genomic profiling in patients with advanced cancer.

Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing

Custom Truck One Source

Gannett Co.

Tactile Systems

Detecting toxic stocks and dumping them at the right time is crucial to avoid big losses. ILMN, TCMD, CTOS and GCI are a few toxic stocks that don't deserve a place in your portfolio.

4 Toxic Stocks to Eliminate From Your Portfolio Now

Natera

10X Genomics

Understanding the State of the Genomics Market

Red-Hot Genomics Plays With Google-Like dominance

U.S. life sciences company Illumina on Thursday criticised EU antitrust regulators for scrutinising its $8 billion cash-and-stock takeover of Grail even though the cancer detection test maker has no activities in Europe.

Illumina blasts EU antitrust regulators over Grail deal scrutiny

Illumina's (ILMN) recent collaboration will allow it to leverage the best-quality synthetic data to remove privacy bottlenecks and accelerate the development of precision medicine.

Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact

SAN DIEGO--(BUSINESS WIRE)-- #privacyengineering--Today, Gretel.ai announced a collaboration with Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, to create privacy-protected, synthetic genomic data that can be accessed by medical researchers anywhere. This announcement includes the release of a successful study the partnership conducted, which proves the viability of significant new use cases for synthetic data in genomics and related fields including medical diagnosi

Gretel and Illumina Partner to Develop Synthetic Data for Genomic Research

SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), today announced that it is supporting a national precision medicine study in Norway to assess the efficacy of blood-based comprehensive genomic profiling (CGP) in cancer therapy selection testing. The study will also evaluate the cost-effectiveness of implementing blood-based CGP in the public healthcare system.

Illumina Supports Norway's Pioneering Precision Medicine Study

Alignment Healthcare

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL announces partnership with Alignment Health Plan as first Medicare Advantage Plan to offer Galleri® multi-cancer early detection blood test.

GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test

Airbnb

Affirm

Confluent

Colfax

Colfax Corp - Units

Dell Technologies

DocuSign

Expedia

Five9

Lemonade

MongoDB

monday.com

Moderna

Netflix

ServiceNow

Okta

PayPal

Take-Two Interactive Software

Twilio

Upstart Holdings

VMware

Zoom Video

Sharp sell-offs can reveal great stock ideas if you surface the right stocks that contrary to the market action close positive. When picking names that close in the green, make sure they are well known and of a higher market cap. They tend to have sustainable rallies when they turn around.

Forget The Covid Apocalypse, Focus On Stocks That Closed Green After Friday's Monster Sell Off

The shares of Illumina, Inc. (NASDAQ: ILMN) have received a price target of $437 from Baird. These are the details.

News for Illumina Stock (ILMN)